Since 2000 the Stock market valuation of the ‘Big Pharma’ companies has dropped sharply. Discuss the causes of the pharmaceutical industry’s current problems and steps that companies are taking to tackle them. By Ali Asgar Kagzi In 1990s‚ pharmaceutical companies were one of the leading shareholder value creators at the stock market. By 1998 the P/E ratio of the Big Pharma companies was twice that of the global stock market and there was a sudden rush among the investors to have a share of
Premium Pharmaceutical industry Pharmacology Drug development
cultural background 4 3) Novartis’ industry: portfolio and mission 5 a) Pharmaceuticals 6 b) Alcon 6 c) Sandoz 6 d) Consumer health 6 e) Vaccines and Diagnostics 7 4) The Novartis’ intercultural characteristics 7 5) The intercultural context of Novartis 7 a) Agreement with the University of California Berkeley - 1998 8 b) Creation of Syngenta – 2000 8 c) Acquisition of Lek Pharmaceuticals – 2002 8 d) Creation of the Novartis Institutes for BioMedical research –
Premium Novartis Pharmaceutical industry Generic drug
Merck & Co.‚ Inc. Recommendation: Buy Target Price Current Price Difference $ 37.09 $ 26.18 41.7%↑ Market Cap. 52 Wk High 52 Wk Low $ 57.48B $ 36.26 $ 25.50 Shrs. Out. 2‚217.6M As of October 21‚ 2005 • Market reaction to Vioxx lawsuits too extreme • Cash flow for company strong enough to absorb potential legal or competitive challenges • Potential blockbuster drugs in the pipeline • A stable of existing drugs to continue driving growth • Aging and growing population
Premium Pharmaceutical industry Pharmacology Food and Drug Administration
Tough on Crime? Pfizer and the CIHR. Healthc Policy [online] 2010 May; 5(4): 16–25. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875889/ [Accessed Oct 26 2012]. Esteban‚ D.‚ 2008. Strengthening corporate social responsibility in the pharmaceutical industry. Journal of Medical Marketing‚ 8(1)‚ pp. 77-79. Kelton‚ E. 2012. Forbes. Big Pharma ’s Offshore Fraud Strategy. [online] Available at: http://www.forbes.com/sites/erikakelton/2012/09/11/big-pharmas-offshore-fraud-strategy/ [Accessed Oct
Premium Business ethics Corporate social responsibility Social responsibility
Subject: Merck‚ the FDA‚ and the Vioxx Recall Facts: Back in 2005‚ Merck was described as a unique force in the pharmaceutical industry; its leadership in profits‚ sales‚ assets‚ and market value was recognized by investors and respected by competitors. Society in general had a favorable reception for the company due to their different acts of generosity‚ like the eternal donation of Mectizan to patients suffering of red blindness. In addition‚ the company has demonstrated high ethical standards
Premium Pharmacology Ethics Clinical trial
acted in a socially responsible and ethical manner with regard to Vioxx. Vioxx is a prescription medicine used to relieve signs and symptoms of arthritis‚ acute pain in adults and painful menstrual cycle and Merck was one of the world’s leading pharmaceutical firms. Corporate social responsibility means that a corporation should act in a way that enhances society and its inhabitants and be held accountable for any of its actions that affect people‚ their communities‚ and their environment. I didn’t
Premium Pharmacology Clinical trial Pharmaceutical industry
They should be approximately 500 words in length each (2 pages). The topics for these two papers are noted below. Refer to at least one outside source in addition to your text as you prepare each of these papers. Application Paper One: New Pharmaceuticals Application Paper Two: Pain Medications The body of the papers should be approximately 500 words (2 pages); there should also be a title page and a reference page. Papers that are too brief or too verbose could be subject to large point deductions
Premium Citation Pharmacology Pharmaceutical drug
Pfizer and the Challenges of the Global Pharmaceutical Industry Overview and Objectives The Pfizer case provides an introduction to external analysis. The case highlights the pharmaceutical industry‚ which has enjoyed extraordinary long-run profitability. The case also demonstrates how broad changes in broad environmental factors (i.e. demographics‚ technology‚ culture‚ etc.) have an impact on industry competition. The case is not especially complex‚ so it is not overwhelming as a first case
Premium Strategic management Pharmaceutical industry
ACKNOWLEDGEMENT I would like to express my gratitude to all those who gave me the possibility to complete this thesis. I would like to thank my college authorities and I am particularly appreciative to Prof. Devendra Jaiswal who gave his time to assist with my requests for information‚ as well as for his guidance and valuable assistance from the offset of this project. His insights and remarks were of great value. I have furthermore to thank Mr. Ashish Dixit ‚ Senior Executive “GLAXO
Premium Pharmaceutical industry Generic drug
The Betapharm Acquisition: DRL ’s Inorganic Growth Strategy in Europe DRL GAINS A FOOTHOLD IN EUROPE On February 15‚ 2006‚ Dr. Reddy ’s Laboratories Limited (DRL)‚ a leading Indian pharmaceutical company‚ acquired the fourth-largest generic pharmaceutical company in Germany‚ betapharm Arzneimittel GmbH (betapharm) from the 3i Group PLC (3i) for US$570 million (480 million). The deal also included the beta institute for socio medical research GmbH ’ (beta Institute)‚ a non-profit research
Premium Generic drug Pharmaceutical industry